Andexanet alfa

安德刹特α

Report date: 2024/03/26 14:29:34

Base Information

Drug NameAndexanet alfa
Drug Alias Name安德刹特αAndexanet alpha安迪珍奈αAndexanet αandexanetum alfa +[14] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant coagulation factor
Mechanisms of ActionProthrombin stimulantsBlood coagulation pathway activation
TargetsProthrombin
Therapy Area/IndicationsDrug-Related Side Effects and Adverse ReactionsBlood Loss, SurgicalHemorrhage +[4] 
Global Approved IndicationsDrug-Related Side Effects and Adverse ReactionsHemorrhageHemorrhagic Disorders
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2018/05/03
Country/TerritoryBelgiumCanadaUnited States +[13] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesPortola Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncAlexion Pharmaceuticals IncAstrazeneca Ab +[7] 
Inactive CompaniesPortola PharmaceuticalsAstrazeneca Plc
Active IndicationsDrug-Related Side Effects and Adverse ReactionsBlood Loss, SurgicalHemorrhage +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeV03AB38
Related LinksWikipediaDrugBankKEGG